Ultragenyx Pharmaceutical | RARE - Spese Di Vendita E Di Amministrazione





Spese Di Vendita E Di Amministrazione Cambiamento Data
Acadia Pharmaceuticals USD 148.57M 12.22M 2026-06
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Alnylam Pharmaceuticals USD 347.92M 65.41M 2026-06
BioCryst Pharmaceuticals USD 63.98M 31.8M 2026-06
BioMarin Pharmaceutical USD 395.55M 137.27M 2026-06
Immunic USD 3.45M 451K 2025-12
Insmed USD 247.47M 208K 2026-06
Ionis Pharmaceuticals USD 130.07M 20.92M 2026-06
Karyopharm Therapeutics USD 10.42M 861K 2026-03
Kyowa Hakko Kirin JPY 43.74B 2.66B 2026-06
MacroGenics USD 9.71M 1.77M 2026-03
Moderna USD 216M 43M 2026-06
Neurocrine Biosciences USD 383.1M 64.6M 2026-06
PTC Therapeutics USD 73.89M 13.31M 2026-03
Puma Biotechnology USD 16.82M 8.15M 2024-09
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Sarepta Therapeutics USD 107.6M 53.57M 2026-06
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Vertex Pharmaceuticals USD 582.2M 88.5M 2026-06